Seres Therapeutics, Inc.
NASDAQ:MCRB
10.08 (USD) • At close April 25, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 126.325 | 7.128 | 144.927 | 33.215 | 34.505 | 28.267 | 32.1 | 21.766 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0.704 | 1.004 | 1.732 | 90.57 | 80.141 | 95.955 | 89.455 | 81.989 | 0.728 | 10.718 | 0 | 0 |
| Gross Profit
| 0 | 125.621 | 6.124 | 143.195 | -57.355 | -45.636 | -67.688 | -57.355 | -60.223 | -0.728 | -10.718 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0.994 | 0.859 | 0.988 | -1.727 | -1.323 | -2.395 | -1.787 | -2.767 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 64.6 | 145.86 | 172.92 | 141.891 | 90.57 | 80.141 | 95.955 | 89.455 | 81.989 | 38.095 | 10.718 | 4.805 | 2.077 |
| General & Administrative Expenses
| 53.183 | 87.744 | 79.694 | 69.261 | 30.775 | 24.748 | 32.596 | 34.04 | 32.616 | 16.761 | 4.364 | 1.247 | 0.956 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 53.183 | 87.744 | 79.694 | 69.261 | 30.775 | 24.748 | 32.596 | 34.04 | 32.616 | 16.761 | 4.364 | 1.247 | 0.956 |
| Other Expenses
| 3.532 | 0 | 1.004 | -1.732 | 0.981 | 1.066 | 0.17 | 0.425 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 121.315 | 233.604 | 253.618 | 209.42 | 121.345 | 104.889 | 128.551 | 123.495 | 114.605 | 54.856 | 15.082 | 6.052 | 3.033 |
| Operating Income
| -121.315 | -107.983 | -246.49 | -64.493 | -88.13 | -71.876 | -100.284 | -91.395 | -92.839 | -54.856 | -15.082 | -6.052 | -3.033 |
| Operating Income Ratio
| 0 | -0.855 | -34.581 | -0.445 | -2.653 | -2.083 | -3.548 | -2.847 | -4.265 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 121.451 | -5.741 | -3.667 | -1.085 | -0.997 | 1.597 | 1.342 | 2.015 | 1.26 | 0.076 | -1.627 | -0.05 | -0.093 |
| Income Before Tax
| 0.136 | -113.724 | -250.157 | -65.578 | -89.127 | -70.279 | -98.942 | -89.38 | -91.579 | -54.78 | -16.709 | -6.102 | -3.126 |
| Income Before Tax Ratio
| 0 | -0.9 | -35.095 | -0.452 | -2.683 | -2.037 | -3.5 | -2.784 | -4.207 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | 3.667 | -4.082 | -2.673 | -6.035 | 1.342 | -1.59 | 2.229 | -0.804 | 1.627 | 0.042 | 0 |
| Net Income
| 0.136 | -113.724 | -253.824 | -61.496 | -86.454 | -64.244 | -98.942 | -89.38 | -91.579 | -54.78 | -16.709 | -6.102 | -3.126 |
| Net Income Ratio
| 0 | -0.9 | -35.609 | -0.424 | -2.603 | -1.862 | -3.5 | -2.784 | -4.207 | 0 | 0 | 0 | 0 |
| EPS
| 0.001 | -0.89 | -2.35 | -0.67 | -1.08 | -1.13 | -2.43 | -2.21 | -2.3 | -2.33 | -0.56 | -0.2 | -0.15 |
| EPS Diluted
| 0.001 | -0.89 | -2.35 | -0.67 | -1.08 | -1.13 | -2.43 | -2.21 | -2.3 | -2.33 | -0.56 | -0.2 | -0.15 |
| EBITDA
| -121.315 | -94.305 | -237.508 | -56.721 | -77.31 | -59.947 | -91.08 | -82.121 | -88.634 | -54.128 | -14.892 | -5.964 | -3.008 |
| EBITDA Ratio
| 0 | -0.747 | -33.32 | -0.391 | -2.328 | -1.737 | -3.222 | -2.558 | -4.072 | 0 | 0 | 0 | 0 |